CEO Chad Robins was paid $9,081,690 in fiscal year 2025, ↑ up 82.6% from fiscal year 2024, the 75th percentile of its disclosed peer group (SEC filing 0001193125-26-177409 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$9,081,690 ↑ Chad Robins total, FY2025 | 75th CEO pay percentile vs peers | 47:1 CEO-to-median pay ratio | 96.67% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ADPT's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chad Robins | $698,258 | $0 | $7,675,100 | $0 | $703,380 | $0 | $4,952 | $9,081,690 |
| Chief Executive Officer and Chairman | ||||||||
| Harlan Robins | 558,653 | — | 7,675,100 | — | 270,823 | — | 4,999 | 8,509,575 |
| Chief Scientific Officer | ||||||||
| Julie Rubinstein | 542,383 | 0 | 3,783,500 | 0 | 273,180 | 0 | 4,932 | 4,603,995 |
| President and Chief Operating Officer | ||||||||
| Susan Bobulsky | 435,750 | 0 | 1,883,990 | 997,325 | 226,013 | 0 | 4,480 | 3,547,558 |
| Chief Commercial Officer, MRD | ||||||||
| Kyle Piskel | 399,950 | 0 | 2,702,500 | 0 | 203,300 | 0 | 4,979 | 3,310,729 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chad Robins | $9,081,690 | $4,973,301 | $8,904,267 | ↑ +4,108,389 |
| Harlan Robins | 8,509,575 | 4,540,286 | 8,611,805 | ↑ +3,969,289 |
| Julie Rubinstein | 4,603,995 | 2,644,553 | 2,971,039 | ↑ +1,959,442 |
| Susan Bobulsky | 3,547,558 | 1,706,700 | 1,455,155 | ↑ +1,840,858 |
| Kyle Piskel | 3,310,729 | 1,290,346 | 744,046 | ↑ +2,020,383 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Adaptive Biotechnologies Corp's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ADPT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Adaptive Biotechnologies Corp Peer Teardown Report
$9,081,690 Chad Robins total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 16, 2026 · Source: 0001193125-26-177409 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ADPT
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ADPT
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses ADPT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ADPT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Adaptive Biotechnologies Corp Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Katey Owen | Independent Director | $309,997 |
| Michael Pellini | Former director (through FY2025) | $276,463 |
| Michelle Griffin | Independent Director | $329,997 |
| Peter Neupert | Lead Independent Director | $354,997 |
| Robert Hershberg | Independent Director | $324,997 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Julie Rubinstein | President and COO | 2026-04-24 | D | 14,722 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-24 | D | 19,060 | 14 | 267,221 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-24 | A | 14,722 | 8 | 124,548 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-27 | A | 14,707 | 8 | 124,421 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-27 | D | 14,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-27 | D | 19,037 | 14 | 270,897 | Common | Form 4 ↗ |
| Kyle Piskel | Chief Financial Officer | 2026-05-18 | D | 3,115 | 13 | 40,620 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 2,009 | 8 | 16,996 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 2,344 | 4 | 9,353 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 39,741 | 17 | 695,070 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 9,376 | 8 | 76,133 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 5,792 | 12 | 70,315 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-06-04 | D | 11,000 | 18 | 198,000 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 9,376 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 2,344 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 2,009 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 5,792 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-06-11 | D | 5,000 | 19 | 95,000 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-06-15 | D | 100,000 | 17 | 1,737,000 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-06-16 | D | 6,160 | 18 | 110,942 | Common | Form 4 ↗ |
| Michelle Griffin | Director | 2026-06-25 | D | 52,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michelle Griffin | Director | 2026-06-25 | D | 52,084 | 20 | 1,051,055 | Common | Form 4 ↗ |
| Michelle Griffin | Director | 2026-06-25 | A | 52,084 | 8 | 406,255 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-06-25 | D | 5,000 | 21 | 102,500 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-26 | A | 11,034 | 12 | 133,953 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-26 | D | 11,034 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-26 | D | 11,034 | 21 | 231,714 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-29 | — | 1,837 | — | — | 1 insider, 1 accrual row | ||
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 51,570 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 24,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 51,570 | 8 | 418,748 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 154,768 | 21 | 3,271,796 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 24,944 | 8 | 211,026 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 1,837 | 12 | 22,301 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 24,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 24,944 | 4 | 99,527 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-07-01 | D | 487 | 22 | 10,714 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 8,743 | 22 | 193,920 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 14,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 14,064 | 8 | 114,200 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 4,688 | 4 | 18,705 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 12,206 | 8 | 103,263 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 3,300 | 12 | 40,062 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 4,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 12,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 3,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 42,261 | 23 | 950,873 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 44,838 | 23 | 1,012,890 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | A | 12,600 | 12 | 152,964 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-02 | D | 146,889 | 22 | 3,297,658 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 12,626 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | A | 12,637 | 8 | 106,909 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | A | 12,626 | 8 | 98,483 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-02 | D | 239,351 | 22 | 5,203,491 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 12,637 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 12,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 105,762 | 23 | 2,389,164 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | A | 22,711 | 8 | 192,135 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 22,711 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 23,677 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 59,374 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | A | 23,677 | 12 | 287,439 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | A | 59,374 | 8 | 463,117 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-07-16 | D | 5,000 | 23 | 115,000 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | D | 284,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | D | 213,702 | 22 | 4,727,088 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | D | 278,698 | 22 | 6,053,321 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | A | 284,800 | 7 | 1,865,440 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-07-30 | D | 1,299 | 24 | 31,176 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-08-10 | D | 3,000 | 25 | 75,000 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 69,690 | 25 | 1,753,400 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 15,000 | 25 | 378,450 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | A | 15,000 | 6 | 94,800 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | D | 321,324 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | D | 318,799 | 25 | 7,995,479 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 40,000 | 25 | 1,004,000 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | D | 2,525 | 26 | 64,564 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | A | 321,324 | 7 | 2,104,672 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | D | 278,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | D | 204 | 25 | 5,129 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | D | 278,472 | 24 | 6,816,995 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | A | 278,676 | 7 | 1,825,328 | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | D | 15,664 | 24 | 382,358 | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | D | 15,000 | 24 | 365,850 | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | A | 15,000 | 6 | 94,800 | Common | Form 4 ↗ |
| Katey Owen | Director | 2026-08-26 | D | 9,615 | 26 | 249,990 | Common | Form 4 ↗ |
| Katey Owen | Director | 2026-08-31 | D | 12,539 | — | — | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-09-15 | D | 1,195 | 27 | 32,265 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 53,091 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 107,537 | 28 | 3,013,187 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 23,442 | 8 | 190,349 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 23,442 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 15,629 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 7,869 | 29 | 224,817 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 15,629 | 4 | 62,360 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 13,398 | 8 | 113,347 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 53,091 | 12 | 644,525 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | D | 6,081 | 28 | 167,653 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | D | 5,800 | 29 | 165,648 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 9,377 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 9,377 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 8,038 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 18,698 | 29 | 534,950 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 8,094 | 28 | 222,747 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | A | 9,377 | 8 | 76,141 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | A | 9,377 | 4 | 37,414 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | A | 8,038 | 8 | 68,001 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-02 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-02 | D | 11,881 | 28 | 334,213 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-02 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | D | 5,182 | 30 | 153,750 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | D | 6,699 | 29 | 193,065 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 901 | 30 | 26,769 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 1,100 | 28 | 31,031 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 9,381 | 27 | 256,664 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 499 | 31 | 15,234 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-10-06 | D | 6,444 | 30 | 193,320 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-07 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-07 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-07 | D | 11,881 | 26 | 313,658 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-08 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-08 | D | 11,881 | 26 | 304,866 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-08 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-09 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-09 | D | 11,881 | 26 | 313,777 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-09 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | D | 2,700 | 26 | 70,389 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | D | 9,181 | 25 | 232,738 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-13 | D | 11,881 | 26 | 302,966 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-13 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-13 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | D | 5,100 | 26 | 131,682 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | D | 6,781 | 26 | 173,390 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-15 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-15 | D | 11,881 | 26 | 304,272 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-15 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | D | 300 | 25 | 7,635 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | D | 11,581 | 24 | 280,376 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Julie Rubinstein | President and COO | 2026-04-24 | D | 14,722 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-24 | D | 19,060 | 14 | 267,221 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-24 | A | 14,722 | 8 | 124,548 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-27 | A | 14,707 | 8 | 124,421 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-27 | D | 14,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-04-27 | D | 19,037 | 14 | 270,897 | Common | Form 4 ↗ |
| Kyle Piskel | Chief Financial Officer | 2026-05-18 | D | 3,115 | 13 | 40,620 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 2,009 | 8 | 16,996 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 2,344 | 4 | 9,353 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 39,741 | 17 | 695,070 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 9,376 | 8 | 76,133 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | A | 5,792 | 12 | 70,315 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-06-04 | D | 11,000 | 18 | 198,000 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 9,376 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 2,344 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 2,009 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-06-04 | D | 5,792 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-06-11 | D | 5,000 | 19 | 95,000 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-06-15 | D | 100,000 | 17 | 1,737,000 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-06-16 | D | 6,160 | 18 | 110,942 | Common | Form 4 ↗ |
| Michelle Griffin | Director | 2026-06-25 | D | 52,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michelle Griffin | Director | 2026-06-25 | D | 52,084 | 20 | 1,051,055 | Common | Form 4 ↗ |
| Michelle Griffin | Director | 2026-06-25 | A | 52,084 | 8 | 406,255 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-06-25 | D | 5,000 | 21 | 102,500 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-26 | A | 11,034 | 12 | 133,953 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-26 | D | 11,034 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-26 | D | 11,034 | 21 | 231,714 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 1,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 51,570 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 24,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 51,570 | 8 | 418,748 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 154,768 | 21 | 3,271,796 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 24,944 | 8 | 211,026 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 1,837 | 12 | 22,301 | Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | D | 24,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 2026-06-29 | A | 24,944 | 4 | 99,527 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-07-01 | D | 487 | 22 | 10,714 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 8,743 | 22 | 193,920 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 14,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 14,064 | 8 | 114,200 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 4,688 | 4 | 18,705 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 12,206 | 8 | 103,263 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | A | 3,300 | 12 | 40,062 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 4,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 12,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 3,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-01 | D | 42,261 | 23 | 950,873 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 44,838 | 23 | 1,012,890 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | A | 12,600 | 12 | 152,964 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-02 | D | 146,889 | 22 | 3,297,658 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 12,626 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | A | 12,637 | 8 | 106,909 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | A | 12,626 | 8 | 98,483 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-02 | D | 239,351 | 22 | 5,203,491 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 12,637 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-02 | D | 12,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 105,762 | 23 | 2,389,164 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | A | 22,711 | 8 | 192,135 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 22,711 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 23,677 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | D | 59,374 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | A | 23,677 | 12 | 287,439 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-07-15 | A | 59,374 | 8 | 463,117 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-07-16 | D | 5,000 | 23 | 115,000 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | D | 284,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | D | 213,702 | 22 | 4,727,088 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | D | 278,698 | 22 | 6,053,321 | Common | Form 4 ↗ |
| Harlan S. Robins | Chief Scientific Officer | 2026-07-21 | A | 284,800 | 7 | 1,865,440 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-07-30 | D | 1,299 | 24 | 31,176 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-08-10 | D | 3,000 | 25 | 75,000 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 69,690 | 25 | 1,753,400 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 15,000 | 25 | 378,450 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | A | 15,000 | 6 | 94,800 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | D | 321,324 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | D | 318,799 | 25 | 7,995,479 | Common | Form 4 ↗ |
| Peter Neupert | Director | 2026-08-17 | D | 40,000 | 25 | 1,004,000 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | D | 2,525 | 26 | 64,564 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-17 | A | 321,324 | 7 | 2,104,672 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | D | 278,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | D | 204 | 25 | 5,129 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | D | 278,472 | 24 | 6,816,995 | Common | Form 4 ↗ |
| Chad M. Robins | Director | 2026-08-18 | A | 278,676 | 7 | 1,825,328 | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | D | 15,664 | 24 | 382,358 | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | D | 15,000 | 24 | 365,850 | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2026-08-18 | A | 15,000 | 6 | 94,800 | Common | Form 4 ↗ |
| Katey Owen | Director | 2026-08-26 | D | 9,615 | 26 | 249,990 | Common | Form 4 ↗ |
| Katey Owen | Director | 2026-08-31 | D | 12,539 | — | — | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-09-15 | D | 1,195 | 27 | 32,265 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 53,091 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 107,537 | 28 | 3,013,187 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 23,442 | 8 | 190,349 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 23,442 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 15,629 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | D | 7,869 | 29 | 224,817 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 15,629 | 4 | 62,360 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 13,398 | 8 | 113,347 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-09-16 | A | 53,091 | 12 | 644,525 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | D | 6,081 | 28 | 167,653 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-01 | D | 5,800 | 29 | 165,648 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 9,377 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 9,377 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 8,038 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 18,698 | 29 | 534,950 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | D | 8,094 | 28 | 222,747 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | A | 9,377 | 8 | 76,141 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | A | 9,377 | 4 | 37,414 | Common | Form 4 ↗ |
| Francis Lo | Chief People Officer | 2026-10-01 | A | 8,038 | 8 | 68,001 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-02 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-02 | D | 11,881 | 28 | 334,213 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-02 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | D | 5,182 | 30 | 153,750 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-05 | D | 6,699 | 29 | 193,065 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 901 | 30 | 26,769 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 1,100 | 28 | 31,031 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 9,381 | 27 | 256,664 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-06 | D | 499 | 31 | 15,234 | Common | Form 4 ↗ |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2026-10-06 | D | 6,444 | 30 | 193,320 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-07 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-07 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-07 | D | 11,881 | 26 | 313,658 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-08 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-08 | D | 11,881 | 26 | 304,866 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-08 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-09 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-09 | D | 11,881 | 26 | 313,777 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-09 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | D | 2,700 | 26 | 70,389 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | D | 9,181 | 25 | 232,738 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-12 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-13 | D | 11,881 | 26 | 302,966 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-13 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-13 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | D | 5,100 | 26 | 131,682 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | D | 6,781 | 26 | 173,390 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-14 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-15 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-15 | D | 11,881 | 26 | 304,272 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-15 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | D | 11,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | D | 300 | 25 | 7,635 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | D | 11,581 | 24 | 280,376 | Common | Form 4 ↗ |
| Julie Rubinstein | President and COO | 2026-10-16 | A | 11,881 | 12 | 144,235 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Susan Bobulsky | RSU | 2025-03-04 | — | — | 119,971 | — | $974,165 |
| Susan Bobulsky | OPTION | 2025-03-04 | — | — | 180,029 | — | 997,325 |
| Julie Rubinstein | RSU | 2025-03-04 | — | — | 175,000 | — | 1,421,000 |
| Harlan Robins | RSU | 2025-03-04 | — | — | 355,000 | — | 2,882,600 |
| Kyle Piskel | RSU | 2025-03-04 | — | — | 125,000 | — | 1,015,000 |
| Chad Robins | RSU | 2025-03-04 | — | — | 355,000 | — | 2,882,600 |
| Julie Rubinstein | RSU | 2025-03-04 | — | — | 175,000 | — | 2,362,500 |
| Chad Robins | RSU | 2025-03-04 | — | — | 355,000 | — | 4,792,500 |
| Harlan Robins | RSU | 2025-03-04 | — | — | 355,000 | — | 4,792,500 |
| Susan Bobulsky | RSU | 2025-03-14 | — | — | 124,976 | — | 909,825 |
| Kyle Piskel | RSU | 2025-03-04 | — | — | 125,000 | — | 1,687,500 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Susan Bobulsky | $1,883,990 | $0 | $997,325 | 0.0% |
| Julie Rubinstein | 3,783,500 | 0 | 0 | 0.0% |
| Harlan Robins | 7,675,100 | 0 | 0 | 0.0% |
| Kyle Piskel | 2,702,500 | 0 | 0 | 0.0% |
| Chad Robins | 7,675,100 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kyle Piskel | RSU | 21,868 | — | $355,136 |
| Kyle Piskel | RSU | 250,000 | — | 4,060,000 |
| Julie Rubinstein | RSU | 350,000 | — | 5,684,000 |
| Robins | RSU | 620,568 | — | 10,078,024 |
| Kyle Piskel | RSU | 10,297 | — | 167,223 |
| Robins | RSU | 710,000 | — | 11,530,400 |
| Robins | RSU | 531,916 | — | 8,638,316 |
| Julie Rubinstein | RSU | 306,250 | — | 4,973,500 |
| Susan Bobulsky | RSU | 124,976 | — | 2,029,610 |
| Kyle Piskel | RSU | 98,445 | — | 1,598,747 |
| Susan Bobulsky | RSU | 119,971 | — | 1,948,329 |
| Julie Rubinstein | RSU | 66,490 | — | 1,079,798 |
| Susan Bobulsky | RSU | 99,735 | — | 1,619,696 |
| Robins | RSU | 61,780 | — | 1,003,307 |
| Julie Rubinstein | RSU | 46,335 | — | 752,480 |
| Kyle Piskel | RSU | 32,805 | — | 532,753 |
| Susan Bobulsky | RSU | 29,552 | — | 479,924 |
| Susan Bobulsky | RSU | 10,297 | — | 167,223 |
| Kyle Piskel | Option | 6,436 | 12.14 | — |
| Susan Bobulsky | Option | 6,436 | 12.14 | — |
| Susan Bobulsky | Option | 27,716 | 8.46 | — |
| Susan Bobulsky | Option | 112,247 | 3.99 | — |
| Susan Bobulsky | Option | 180,029 | 8.12 | — |
| Robins | Option | 38,612 | 12.14 | — |
| Julie Rubinstein | Option | 28,959 | 12.14 | — |
| Julie Rubinstein | Option | 62,360 | 8.46 | — |
The company targets total compensation at or near the market median of the peer group, with flexibility to adjust based on experience and performance. The program emphasizes pay-for-performance by delivering a majority of compensation through variable pay, with at least 50% of target compensation in equity and at least 50% of equity grants in the form of performance stock units (PSUs).
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy Consulting Group, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-05 | 125,287,618 | 4,316,144 | 158,599 | 96.67% | Passed |
| 2025 | 2025-06-10 | 126,126,999 | 1,580,695 | 397,868 | 98.76% | Passed |
| 2024 | 2024-06-07 | 103,594,016 | 15,410,744 | 1,454,950 | 87.05% | Passed |
| 2023 | 2023-06-09 | 89,592,587 | 17,467,529 | 1,294,424 | 83.68% | Passed |
| 2022 | 2022-06-10 | 72,717,583 | 44,482,886 | 298,416 | 62.05% | Passed |
| 2021 | 2021-06-11 | 100,345,226 | 7,888,977 | 146,572 | 92.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-05 | 96.67%a |
| 2025 | 2025-06-10 | 98.76%b |
| 2024 | 2024-06-07 | 87.05%c |
a. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.
b. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.
c. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 47 : 1 |
|---|---|
| CEO total compensation | $9,081,690 |
| Median employee compensation | $194,620 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter NeupertIndependent · Lead Independent Director · Audit Committee · Compensation and Human Capital Committee · Nominating and Corporate Governance Committee (Chair) | $105,000 | $124,999 | $124,998 | — | — | $354,997 |
| Michelle GriffinIndependent · Audit Committee (Chair) | 80,000 | 124,999 | 124,998 | — | — | 329,997 |
| Robert HershbergIndependent · Compensation and Human Capital Committee (Chair) · Nominating and Corporate Governance Committee | 75,000 | 124,999 | 124,998 | — | — | 324,997 |
| Katey OwenIndependent · Audit Committee · Compensation and Human Capital Committee | 60,000 | 124,999 | 124,998 | — | — | 309,997 |
| Michael PelliniIndependent · Not standing for re-election · Departed during FY | 26,466 | 124,999 | 124,998 | — | — | 276,463 |
| Chad RobinsEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $180,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $346,466 |
| Equity awards (grant-date value) | $624,995 |
| All other compensation | $0 |
| Total cost of the board | $971,461 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Adaptive Biotechnologies Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Adaptive Biotechnologies Corp.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Natera, Inc. | 2025 | Steven Chapman | $853,710 | $12,979,558 | $0 | $1,114,151 | $14,957,319 |
| 2 | Twist Bioscience Corporation | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 3 | Immunocore Holdings plc | 2025 | Bahija Jallal | 765,000 | 2,819,992 | 6,579,990 | 688,500 | 10,885,268 |
| 4 | Maravai LifeSciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 5 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 6 | Adaptive Biotechnologies Corp | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 7 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 8 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 9 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 10 | Sage Therapeutics, Inc. | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 11 | Castle Biosciences, Inc. | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 12 | Mesa Laboratories, Inc. | 2026 | Gary Owens | 808,846 | 4,700,017 | 0 | 1,120,000 | 6,643,208 |
| 13 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 14 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 15 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 16 | Recursion Pharmaceuticals, Inc. | 2025 | Najat Khan | 600,000 | 1,944,547 | 2,501,058 | 256,777 | 5,349,065 |
| 17 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 18 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 19 | bluebird bio, Inc. | 2023 | Andrew Obenshain | 681,657 | 863,590 | 1,142,440 | 348,024 | 3,049,181 |
| 20 | Voyager Therapeutics, Inc. | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 21 | Codexis, Inc. | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Adaptive Biotechnologies Corp | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| bluebird bio, Inc. | 85% | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Aon plc (Human Capital Solutions practice) |
| CareDx, Inc. | 122% | RSU 70 · PSU 30 | No | Alpine Rewards |
| Castle Biosciences, Inc. | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Codexis, Inc. | 95% | not disclosed | not disclosed | Pearl Meyer |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Immunocore Holdings plc | 120% | Options 70 · RSU 30 | not disclosed | Aon |
| Maravai LifeSciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Mesa Laboratories, Inc. | 125% | PSU 50 · RSU 50 | No | Frederic W. Cook & Co, Inc. |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Recursion Pharmaceuticals, Inc. | 80% | RSU 50 · Option 50 | not disclosed | Compensia |
| Sage Therapeutics, Inc. | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
| Voyager Therapeutics, Inc. | 97.5% | not disclosed | No | Alpine Rewards, LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Chad Robins | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Summary Compensation Table” · page 33. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 2 | Section 01, Harlan Robins | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Summary Compensation Table” · page 33. As printed: 8,509,575. Filing ↗ |
| 3 | Section 01, Julie Rubinstein | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Summary Compensation Table” · page 33. As printed: 4,603,995. Filing ↗machine: span 949713–949722 |
| 4 | Section 01, Susan Bobulsky | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Summary Compensation Table” · page 33. As printed: 3,547,558. Filing ↗machine: span 884205–884214 |
| 5 | Section 01, Kyle Piskel | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Summary Compensation Table” · page 33. As printed: 3,310,729. Filing ↗machine: span 851463–851472 |
| 6 | Section 03, Susan Bobulsky RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Susan Bobulsky OPTION | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1102002–1102009 |
| 8 | Section 03, Julie Rubinstein RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 9 | Section 03, Harlan Robins RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Kyle Piskel RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 11 | Section 03, Chad Robins RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1027377–1027386 |
| 12 | Section 03, Julie Rubinstein RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1176833–1176842 |
| 13 | Section 03, Chad Robins RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1038225–1038234 |
| 14 | Section 03, Harlan Robins RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1144817–1144826 |
| 15 | Section 03, Susan Bobulsky RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1112849–1112856 |
| 16 | Section 03, Kyle Piskel RSU | DEF 14A | 1900-01-01 | 0001193125-26-177409 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1070188–1070197 |
| 17 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “CEO Pay Ratio”. As printed: 47 : 1. Filing ↗ |
| 18 | Section 08, Peter Neupert | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Director Compensation”. As printed: 354,997. Filing ↗machine: span 415969–416178 |
| 19 | Section 08, Michelle Griffin | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Director Compensation”. As printed: 329,997. Filing ↗machine: span 403684–403893 |
| 20 | Section 08, Robert Hershberg | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Director Compensation”. As printed: 324,997. Filing ↗machine: span 409832–410041 |
| 21 | Section 08, Katey Owen | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Director Compensation”. As printed: 309,997. Filing ↗machine: span 422107–422316 |
| 22 | Section 08, Michael Pellini | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Director Compensation”. As printed: 276,463. Filing ↗machine: span 428249–428458 |
| 23 | Section 08, Chad Robins | DEF 14A | 2026-04-24 | 0001193125-26-177409 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 24 | Section 02, Julie Rubinstein 2026-04-24 | Form 4 | 2026-04-24 | 0001780664-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Julie Rubinstein 2026-04-24 | Form 4 | 2026-04-24 | 0001780664-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Julie Rubinstein 2026-04-24 | Form 4 | 2026-04-24 | 0001780664-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Julie Rubinstein 2026-04-27 | Form 4 | 2026-04-29 | 0001780664-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Julie Rubinstein 2026-04-27 | Form 4 | 2026-04-29 | 0001780664-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Julie Rubinstein 2026-04-27 | Form 4 | 2026-04-29 | 0001780664-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Kyle Piskel 2026-05-18 | Form 4 | 2026-05-20 | 0001780662-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Susan Bobulsky 2026-06-04 | Form 4 | 2026-06-08 | 0001820885-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Francis Lo 2026-06-04 | Form 4 | 2026-06-08 | 0001780660-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Susan Bobulsky 2026-06-11 | Form 4 | 2026-06-15 | 0001820885-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Harlan S. Robins 2026-06-15 | Form 4 | 2026-06-17 | 0001780851-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Harlan S. Robins 2026-06-16 | Form 4 | 2026-06-17 | 0001780851-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Michelle Griffin 2026-06-25 | Form 4 | 2026-06-29 | 0001229765-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Michelle Griffin 2026-06-25 | Form 4 | 2026-06-29 | 0001229765-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Michelle Griffin 2026-06-25 | Form 4 | 2026-06-29 | 0001229765-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Susan Bobulsky 2026-06-25 | Form 4 | 2026-06-29 | 0001820885-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Sharon Benzeno 2026-06-26 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Sharon Benzeno 2026-06-26 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Sharon Benzeno 2026-06-26 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Sharon Benzeno 2026-06-29 | Form 4 | 2026-06-30 | 0001780854-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Susan Bobulsky 2026-07-01 | Form 4 | 2026-07-06 | 0001820885-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Francis Lo 2026-07-01 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Harlan S. Robins 2026-07-02 | Form 4 | 2026-07-07 | 0001780851-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Harlan S. Robins 2026-07-02 | Form 4 | 2026-07-07 | 0001780851-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Francis Lo 2026-07-02 | Form 4 | 2026-07-06 | 0001780660-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Francis Lo 2026-07-15 | Form 4 | 2026-07-17 | 0001780660-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Susan Bobulsky 2026-07-16 | Form 4 | 2026-07-20 | 0001820885-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Harlan S. Robins 2026-07-21 | Form 4 | 2026-07-23 | 0001780851-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Harlan S. Robins 2026-07-21 | Form 4 | 2026-07-23 | 0001780851-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Harlan S. Robins 2026-07-21 | Form 4 | 2026-07-23 | 0001780851-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Harlan S. Robins 2026-07-21 | Form 4 | 2026-07-23 | 0001780851-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Susan Bobulsky 2026-07-30 | Form 4 | 2026-08-03 | 0001820885-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Susan Bobulsky 2026-08-10 | Form 4 | 2026-08-12 | 0001820885-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Peter Neupert 2026-08-17 | Form 4 | 2026-08-19 | 0001237566-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Peter Neupert 2026-08-17 | Form 4 | 2026-08-19 | 0001237566-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Peter Neupert 2026-08-17 | Form 4 | 2026-08-19 | 0001237566-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Peter Neupert 2026-08-17 | Form 4 | 2026-08-19 | 0001237566-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Chad M. Robins 2026-08-17 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Chad M. Robins 2026-08-17 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Peter Neupert 2026-08-17 | Form 4 | 2026-08-19 | 0001237566-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Chad M. Robins 2026-08-17 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Chad M. Robins 2026-08-17 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Chad M. Robins 2026-08-18 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Chad M. Robins 2026-08-18 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Chad M. Robins 2026-08-18 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Chad M. Robins 2026-08-18 | Form 4 | 2026-08-19 | 0001780649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Robert Hershberg 2026-08-18 | Form 4 | 2026-08-20 | 0001274139-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Robert Hershberg 2026-08-18 | Form 4 | 2026-08-20 | 0001274139-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Robert Hershberg 2026-08-18 | Form 4 | 2026-08-20 | 0001274139-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Robert Hershberg 2026-08-18 | Form 4 | 2026-08-20 | 0001274139-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Katey Owen 2026-08-26 | Form 4 | 2026-08-28 | 0001852578-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Katey Owen 2026-08-31 | Form 4 | 2026-09-02 | 0001852578-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Susan Bobulsky 2026-09-15 | Form 4 | 2026-09-17 | 0001820885-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Francis Lo 2026-09-16 | Form 4 | 2026-09-18 | 0001780660-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Julie Rubinstein 2026-10-01 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Julie Rubinstein 2026-10-01 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Julie Rubinstein 2026-10-01 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Julie Rubinstein 2026-10-01 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Francis Lo 2026-10-01 | Form 4 | 2026-10-05 | 0001780660-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Julie Rubinstein 2026-10-02 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Julie Rubinstein 2026-10-02 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Julie Rubinstein 2026-10-02 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Julie Rubinstein 2026-10-05 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Julie Rubinstein 2026-10-05 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Julie Rubinstein 2026-10-05 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Julie Rubinstein 2026-10-05 | Form 4 | 2026-10-05 | 0001780664-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Julie Rubinstein 2026-10-06 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Julie Rubinstein 2026-10-06 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Julie Rubinstein 2026-10-06 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Julie Rubinstein 2026-10-06 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Julie Rubinstein 2026-10-06 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Julie Rubinstein 2026-10-06 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Susan Bobulsky 2026-10-06 | Form 4 | 2026-10-08 | 0001820885-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Julie Rubinstein 2026-10-07 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Julie Rubinstein 2026-10-07 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Julie Rubinstein 2026-10-07 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Julie Rubinstein 2026-10-08 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Julie Rubinstein 2026-10-08 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Julie Rubinstein 2026-10-08 | Form 4 | 2026-10-08 | 0001780664-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Julie Rubinstein 2026-10-09 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Julie Rubinstein 2026-10-09 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Julie Rubinstein 2026-10-09 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Julie Rubinstein 2026-10-12 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Julie Rubinstein 2026-10-12 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Julie Rubinstein 2026-10-12 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Julie Rubinstein 2026-10-12 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Julie Rubinstein 2026-10-13 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Julie Rubinstein 2026-10-13 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Julie Rubinstein 2026-10-13 | Form 4 | 2026-10-13 | 0001780664-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Julie Rubinstein 2026-10-14 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Julie Rubinstein 2026-10-14 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Julie Rubinstein 2026-10-14 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Julie Rubinstein 2026-10-14 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Julie Rubinstein 2026-10-15 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Julie Rubinstein 2026-10-15 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Julie Rubinstein 2026-10-15 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Julie Rubinstein 2026-10-16 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Julie Rubinstein 2026-10-16 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Julie Rubinstein 2026-10-16 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Julie Rubinstein 2026-10-16 | Form 4 | 2026-10-16 | 0001780664-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 06, 2026 vote | Form 8-K | 2026-06-09 | 0001193125-26-263844 | Item 5.07 · say-on-pay result. As reported: 96.67% (votes for as printed: 125,287,618). Filing ↗ |
| 180 | Section 06, 2025 vote | Form 8-K | 2025-06-12 | 0001193125-25-140017 | Item 5.07 · say-on-pay result. As reported: 98.76% (votes for as printed: 126,126,999). Filing ↗ |
| 181 | Section 06, 2024 vote | Form 8-K | 2024-06-11 | 0000950170-24-071913 | Item 5.07 · say-on-pay result. As reported: 87.05% (votes for as printed: 103,594,016). Filing ↗ |
| 182 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 183 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 184 | Section 09b board cost (computed) | Computed | — | — | Cash 346,466 + equity 624,995 + all other 0 = 971,461, summed across the director compensation table rows.machine: formula: Σ = 971,461 |
| 185 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 186 | Twist Bioscience Corporation, Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 187 | Immunocore Holdings plc, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001140361-26-015122 | CEO total compensation as printed in Immunocore Holdings plc's own proxy. As printed: 10,885,268. Filing ↗machine: r2 · c24 · span 670285–670295 |
| 188 | Maravai LifeSciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 189 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 190 | Adaptive Biotechnologies Corp (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177409 | CEO total compensation as printed in Adaptive Biotechnologies Corp's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 191 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 192 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 193 | CareDx, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 194 | Sage Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-058060 | CEO total compensation as printed in Sage Therapeutics, Inc.'s own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793 |
| 195 | Castle Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001628280-26-024166 | CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096 |
| 196 | Mesa Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0000724004-26-000071 | CEO total compensation as printed in Mesa Laboratories, Inc.'s own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955 |
| 197 | Fulgent Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001674930-26-000020 | CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288 |
| 198 | Allogene Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 199 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996 |
| 200 | Recursion Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001601830-26-000065 | CEO total compensation as printed in Recursion Pharmaceuticals, Inc.'s own proxy. As printed: 5,349,065. Filing ↗machine: r5 · c24 · span 551909–551918 |
| 201 | Quanterix Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 202 | Pacific Biosciences of California, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 203 | bluebird bio, Inc., Section 10b CEO total | DEF 14A | 2024-09-26 | 0001293971-24-000049 | CEO total compensation as printed in bluebird bio, Inc.'s own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796 |
| 204 | Voyager Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050297 | CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. Filing ↗machine: t9 · r1 · c47 · span 370852–370861 |
| 205 | Codexis, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186994 | CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937 |
| 206 | Section 10a, Sage Therapeutics, Inc. reciprocity | DEF 14A | — | 0000950170-25-058060 | Sage Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 207 | Section 10a, Quanterix Corporation reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix Corporation names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 208 | Section 10a, Voyager Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050297 | Voyager Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 209 | Section 10a, Immunocore Holdings plc reciprocity | DEF 14A | — | 0001140361-26-015122 | Immunocore Holdings plc's most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 210 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 211 | Section 10a, Allogene Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 212 | Section 10a, CareDx, Inc. reciprocity | DEF 14A | — | 0001217234-26-000028 | CareDx, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 213 | Section 10a, Castle Biosciences, Inc. reciprocity | DEF 14A | — | 0001628280-26-024166 | Castle Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 214 | Section 10a, Codexis, Inc. reciprocity | DEF 14A | — | 0001193125-25-093503 | Codexis, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 215 | Section 10a, Fulgent Genetics, Inc. reciprocity | DEF 14A | — | 0001674930-26-000020 | Fulgent Genetics, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 216 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 217 | Section 10a, Maravai LifeSciences Holdings, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeSciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗ |
| 218 | Section 10a, Mesa Laboratories, Inc. reciprocity | DEF 14A | — | 0000724004-26-000071 | Mesa Laboratories, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 219 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 220 | Section 10a, Pacific Biosciences of California, Inc. reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 221 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Adaptive Biotechnologies Corp Executive Compensation Report
$1,500